Study of Interventional Pulmonologic Treatment of Malignant Central Airway Stricture

Prospective, Open, Multicenter Study of Interventional Pulmonologic Treatment of Malignant Central Airway Stricture

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02299830

Enrollment

200

Registered

2014-11-24

Start date

2014-12-31

Completion date

2017-12-31

Last updated

2014-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Obstruction

Keywords

neoplasm, central airway, obstruction

Brief summary

The purpose of this study is to evaluate the efficacy and safety of four interventional pulmonology techniques for the treatment of malignant central airway stricture. The four techniques are： * cryotherapy * argon plasma coagulation * stent * snare

Interventions

PROCEDUREcryotherapy

use cryotherapy to delete soft neoplasm tissue in the airway

PROCEDUREargon plasma coagulation

use argon plasma coagulation to delete hard neoplasm tissue in the airway

PROCEDUREstent placement

use stent placement to open the airway compressed by out neoplasm

PROCEDUREdeletion tumor tissue by snare

use snare to delete polypoid neoplasm tissue in the airway

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* malignant neoplasm caused central airway stenosis * the degree of stenosis is above 50% * estimated survival duration is longer than 3 months * received no treatment one month before * can understand the statement informed consent * agree to enroll in the study

Exclusion criteria

* older than 70 years or younger than 18 years * not malignant neoplasm caused central airway stenosis * not central airway stenosis * existence of lumina collapse or twisting * severe arrhythmia, myocardial ischemia or hypertensive crisis * coagulation disorders * existence of severe organ disfunction * allergic to anesthesia drugs * refuse to participate the study

Design outcomes

Primary

Measure	Time frame
percentage of the cases that got Ⅰand Ⅱlevel remission	the next day after the treatment

Secondary

Measure	Time frame
the values of dyspnea index	the next day after the treatment
Karnofsky Physical scales	the next day after the treatment

Other

Measure	Time frame
adverse event during the treatment	from the beginning of the treatment to 48 hours after the treatment

Countries

China

Contacts

Primary ContactDeguang Mu, Ph.D

deguang@fmmu.edu.cn86-29-777825

Backup ContactYandong Nan, MD

nanyandong2008@163.com86-29-84717533

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026